Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 18/20 | 0.54 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672760 | 0.96 | KCNQ2 (0.58) | KCNQ2KCNQ3CSNK1D | |
| SCHEMBL3679813 | 0.87 | KCNQ2 (0.56) | KCNQ2KCNQ3 | |
| SCHEMBL30794834 | 0.86 | KCNQ2 (0.72) | KCNQ2KCNQ3 | |
| SCHEMBL1000113 | 0.86 | KCNQ2 (0.72) | KCNQ2KCNQ3 | |
| SCHEMBL12075634 | 0.86 | KCNQ2 (0.48) | KCNQ2KCNQ3 | |
| SCHEMBL4945977 | 0.85 | KCNQ2 (0.74) | KCNQ2KCNQ3 | |
| SCHEMBL12955204 | 0.85 | KCNQ2 (0.51) | KCNQ2KCNQ3 | |
| SCHEMBL13797519 | 0.83 | KCNQ2 (0.52) | KCNQ2KCNQ3 | |
| SCHEMBL12954969 | 0.83 | KCNQ2 (0.55) | KCNQ2KCNQ3 | |
| SCHEMBL1000318 | 0.82 | KCNQ2 (0.78) | KCNQ2KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367684-B2 | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2170861-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2170861-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20080318979-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157404-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318979-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | KCNH2, KCNA6, KCNA1 | KCNQ2 24/4885KCNQ3 32/4885TRPV3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.